Viking Therapeutics, Inc. (VKTX) Stock Analysis — Probabli.AI
AI-powered analysis for VKTX (Viking Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Bullish.
Last price: $32.98 · Market cap: $3.7B · AI consensus: Bullish
Viking Therapeutics demonstrates high potential in the biopharmaceutical sector, particularly through its flagship VK2809, with strong advances in clinical trials. Analyst sentiment, significant pipeline opportunities, and projected milestones make this a compelling investment, albeit with substantial competitive and financial risks. Mixed near-term developments are outweighed by long-term growth…
Probabilistic 1-Year Outlook
- Bull 4000% · Neutral 4500% · Bear 1500%
- Viking Therapeutics has strong potential backed by positive drug development updates, analyst confidence with highly elevated price targets, and meaningful strides in advancing VK2809. However, it faces execution risks,…
5-Year Outlook
- Bull 5000% · Neutral 3000% · Bear 2000%
SWOT Highlights
- Strength: Strong pipeline with VK2809 showing promising results.
- Strength: Analyst consensus implies significant upside potential.
- Risk: Negative average EPS surprise indicates possible forecasting or execution issues.
- Risk: Cash burn rate exhibits financial strain concerns.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate VKTX a BUY with a mean price target of $88.
Analysis generated Mar 8, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/VKTX.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.